Acquired platelet antagonism: off‐target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors
Author(s): ,
B. M. E. Tullemans
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
,
J. W. M. Heemskerk
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
M. J. E. Kuijpers
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
Correspondence: Marijke J. E. Kuijpers, Department of Biochemistry (CARIM), Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands|Tel.: +31 43 388 1537|E‐mail: Marijke.Kuijpers@maastrichtuniversity.nl
ISTH Academy. Kuijpers M. Sep 4, 2018; 230961
Marijke Kuijpers
Marijke Kuijpers
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.
Journal Abstract
Discussion Forum (0)
Rate & Comment (0)




Keyword(s)
cancer, platelets, signaling, therapy, tyrosine kinase inhibitor
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies